Biohaven (BHVN) Expected to Announce Earnings on Monday

Biohaven (NYSE:BHVN) is expected to be posting its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Biohaven Stock Up 3.1%

NYSE:BHVN opened at $11.50 on Friday. The stock’s fifty day moving average price is $11.57 and its two-hundred day moving average price is $12.76. Biohaven has a 52-week low of $7.48 and a 52-week high of $37.36. The company has a debt-to-equity ratio of 1.91, a quick ratio of 2.86 and a current ratio of 2.86. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -1.51 and a beta of 1.14.

Analyst Upgrades and Downgrades

BHVN has been the subject of a number of recent research reports. Bank of America downgraded Biohaven from a “buy” rating to a “neutral” rating and set a $10.00 target price for the company. in a research report on Wednesday, November 5th. BTIG Research reissued a “buy” rating and set a $16.00 price objective on shares of Biohaven in a report on Tuesday, November 18th. UBS Group downgraded shares of Biohaven from a “buy” rating to a “neutral” rating and cut their target price for the company from $26.00 to $11.00 in a research report on Wednesday, November 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Biohaven in a research report on Monday, December 29th. Finally, The Goldman Sachs Group raised Biohaven to a “strong-buy” rating in a research note on Friday, February 6th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Biohaven currently has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Hedge Funds Weigh In On Biohaven

Several institutional investors have recently modified their holdings of the business. Invesco Ltd. increased its stake in Biohaven by 59.0% during the 4th quarter. Invesco Ltd. now owns 194,751 shares of the company’s stock worth $2,199,000 after purchasing an additional 72,230 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Biohaven during the fourth quarter worth $342,000. XTX Topco Ltd raised its holdings in shares of Biohaven by 31.1% during the fourth quarter. XTX Topco Ltd now owns 83,455 shares of the company’s stock worth $942,000 after acquiring an additional 19,816 shares during the period. Voloridge Investment Management LLC lifted its position in Biohaven by 758.4% in the 4th quarter. Voloridge Investment Management LLC now owns 1,318,775 shares of the company’s stock valued at $14,889,000 after acquiring an additional 1,165,137 shares in the last quarter. Finally, Virtus Investment Advisers LLC boosted its stake in Biohaven by 216.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 23,072 shares of the company’s stock worth $260,000 after purchasing an additional 15,773 shares during the period. Institutional investors own 88.78% of the company’s stock.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.